IP48: Infections/Inflammation/Cystic Disease of the Genitourinary Tract: Kidney & Bladder II
Saturday, May 16, 2026 3:30 PM to 5:30 PM · 2 hr. (America/New_York)
147B
Poster and Podium Sessions
Infection/Inflammation
Saturday, May 16
IP48-01: LONG-TERM SAFETY AND EFFICACY OF CHRONIC NITROFURANTOIN PROPHYLAXIS IN POST-MENOPAUSAL WOMEN WITH RECURRENT URINARY TRACT INFECTIONS
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-02: Drugs associated the most with Retroperitoneal Fibrosis: assessment of the 1969-2025 Food and Drug Administration (FDA) pharmacovigilance database
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-03: INTRAVESICAL AMINOGLYCOSIDES FOR THE TREATMENT OF ACUTE BACTERIAL URINARY TRACT INFECTIONS
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-04: Comparison of SIRS criteria and qSOFA score for predicting severe acute kidney injury development and mortality in febrile urinary tract infection
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-05: Extended-Spectrum Beta-Lactamase-Producing E. coli in Pyelonephritis: Tripling Hospital Stay—The Clinical and Systemic Cost of Antimicrobial Resistance
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-06: Variability in Pre- and Post-operative Antibiotic Prescription Rates and Impact on Infection Outcomes After Ureteroscopy
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-07: Adjuvant Immunomodulation for the Prevention of Recurrent Urinary Tract Infections. (AIPIRUTI Pilot Study)
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-08: An outbreak of multi-drug resistant Pseudomonas aeruginosa infections following flexible ureteroscopic stone removal
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
Sin Woo Lee
IP48-09: From Routine to Restricted: Impact of the FDA Black Box Warning on Fluoroquinolones on the Treatment of Simple Cystitis in Women
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-10: Fluoroquinolone Prescribing Patterns for Uncomplicated UTI: Insights from Three Large Health Systems.
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-11: European Commission 2019 fluoroquinolone restrictions: difference-in-differences shows Poland’s excess defined daily doses versus the European Union/European Economic Area without short-term Escherichia coli resistance benefit
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-12: Ten-Year Trends in Antimicrobial Resistance in Outpatient Urinary Tract Infections: 153,198 Urine Cultures from São Paulo, Brazil
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-13: The prevalence of mycoplasmataceae infections in urologic patients screened in a large, academic, outpatient setting
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-14: Flipping a coin: state-by-state analysis reveals resistance gene detection concordance with phenotypic antibiotic susceptibility in urinary tract infection diagnostic testing averages 50 percent
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-15: Epidemiology and Treatment Patterns of Retroperitoneal Fibrosis: A Real-World Analysis Using the TriNetX Research Network
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-16: Risk of Urinary Tract Infections, Pyelonephritis, and Sepsis in Patients with Type 2 Diabetes Mellitus on SGLT2 Inhibitors: A Real-World Multicenter Cohort Study
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-17: Safety of Continuing SGLT-2 Inhibitors During Ureteroscopy: Infection and Retention Outcomes in Real-World Diabetic Patients
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-18: Adjunctive glucocorticoids following decompression of an infected, obstructed urinary tract
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-19: Outcome of Guideline-Directed Pre-Operative Prophylactic Single Dose/Day vs Extended Prophylactic Antibiotics for Urological Surgeries: A Randomized Controlled Study
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
Rishi Nayyar
IP48-20: AtbFinder: A Novel Diagnostic Test That Improves Antibiotic Selection and Clinical Outcomes in UTI-Associated Cognitive Decline and Delirium in Patients with Neurodegenerative Disorders
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-21: Assessing the Lodestar Dx Uropathogen Identifier as a Rapid Diagnostic Alternative to Conventional Urine Culture and Dipstick for Pre-operative Screening.
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-22: Optimising Outpatient Urology Care with the Lodestar Dx Rapid Urine Analyser: Real-Time Uropathogen Identification and Antibiotic Stewardship.
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-23: The Hidden Mental Burden of Recurrent Lower Urinary Tract Infections: Exploring the Influence of Gender and Urologic Co-morbidities on Anxiety and Depression
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-24: Electrical Impedance Profiling of Urine Samples for Rapid Gram negative Bacterial Detection
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
Benedetto Calabrese · Humanitas University
IP48-25: Conservative Management of Patients with Unilateral Hydronephrosis: Not Everyone Needs a Stent
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-26: Comparison of infectious outcomes following video urodynamics versus voiding cystourethrogram in a pediatric cohort
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-27: Effectiveness of Double-Dose MV140 in Patients with Recurrent Urinary Tract Infections Secondary to Neuropathic Bladder of Multiple Aetiologies
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-28: Emergency Department Utilization and Infections after Artificial Urinary Sphincter vs Male Urethral Sling: A Matched Cohort Analysis of 30 day and 90 day Outcomes
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
IP48-29: A Multi-Institutional Histopathological Examination of Ureteropelvic Junction Obstruction Yields Insights into its Pathogenesis
Saturday, May 16, 2026 3:30 PM to 5:30 PM
147B
